Review
Tumor-Associated Macrophages and Inflammatory Microenvironment in Gastric Cancer: Novel Translational Implications

Karim Rihawi 1,4, Angela Dalia Ricci 1,4, Alessandro Rizzo 1, Stefano Brocchi 2, Giovanni Marasco 3, Luigi Vincenzo Pastore 2, Fabiola Lorena Rojas Llimpe 1, Rita Golfieri 2,†,‡ and Matteo Renzulli 2,*,‡

1 Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy; karim.rihawi@gmail.com (K.R.); dalia.ricci@gmail.com (A.D.R.); alessandrorizzo1990@virgilio.it (A.R.); fabiolalorenarojas@unibo.it (F.L.R.L.)
2 Department of Radiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy; stefano.brocchi85@gmail.com (S.B.); luigi.pastore3@studio.unibo.it (L.V.); rita.golfieri@unibo.it (R.G.)
3 Department of Medical and Surgical Sciences, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy; giovannimarasco89@gmail.com
* Correspondence: matteo.renzulli@aosp.bo.it; Tel.: +39-0512142958; Fax: +39-0512142805
† K.R. and A.D.R. joint first authorship.
‡ R.G. and M.R. joint last authorship.

Abstract: Gastric cancer (GC) represents the fifth most frequently diagnosed cancer worldwide, with a poor prognosis in patients with advanced disease despite many improvements in systemic treatments in the last decade. In fact, GC has shown resistance to several treatment options, and thus, notable efforts have been focused on the research and identification of novel therapeutic targets in this setting. The tumor microenvironment (TME) has emerged as a potential therapeutic target in several malignancies including GC, due to its pivotal role in cancer progression and drug resistance. Therefore, several agents and therapeutic strategies targeting the TME are currently under assessment in both preclinical and clinical studies. The present study provides an overview of available evidence of the inflammatory TME in GC, highlighting different types of tumor-associated cells and implications for future therapeutic strategies.

Keywords: gastric cancer; tumor microenvironment; tumor-associated macrophages; tumor-associated fibroblasts; lymphocytes

1. Introduction
Gastric cancer (GC) is the fifth most diagnosed malignancy worldwide and represents the third leading cause of cancer deaths worldwide [1], despite differences in incidence and mortality among East Asia, Eastern Europe, and South America [2]. Immunotherapy has drastically improved the treatment options for many solid tumors; in advanced GC, the combination of chemotherapy and immunotherapy seems the most promising approach, based on the results of the CheckMate 649 study presented at the last European Society of Medical Oncology (ESMO) 2020 virtual meeting [3,4]. Nevertheless, the prognosis of GC patients remains dismal at present, since more than half of the patients are diagnosed at an advanced and/or metastatic stage of the disease, with a median overall survival time of roughly 1 year [2,5,6].

GC has traditionally been classified into two major histological subtypes, intestinal and diffuse, according to Lauren’s criteria, while the World Health Organization developed a more complex histological classification for GC, including many subtypes, some of which are very uncommon [7,8]. The main limitation of these histological classifications relies on the inability to successfully drive to histologic subtype-specific therapeutic approaches. In 2014, the Cancer Genome Atlas (TCGA) Network proposed a pioneering molecular classification, which not only provides a clearer definition of the GC biology but also
has therapeutic implications [9–11]; according to this classification, GC encompasses four
different molecular subtypes: Epstein–Barr virus-positive (9%), microsatellite instable
(22%), genomically stable (20%), and chromosomal unstable (50%) [9].

On the other hand, understanding the different interactions between tumor cells, chronic
inflammation, and the immune tumor microenvironment (TME) represents an unsolved clin-
ical issue necessary for identifying and developing tailored therapies for GC, particularly for
non-responder patients [12]. The TME consists of different types of cells, including immune
and inflammatory cells such as lymphocytes and macrophages; stromal cells such as fibro-
blasts, adipocytes, and pericytes; small organelles; RNA; blood vessels and lymph vessels; the
extracellular matrix (ECM), and secreted proteins. The persistent inflammatory state induced
by Helicobacter Pylori (HP) infection and the affected gastric secretory function is supposed
to play a crucial role in the transformation from chronic atrophic gastritis to metaplasia, ep-
ithelial dysplasia, and, eventually, adenocarcinoma [13]. There is also emerging evidence of
several cell types involved in the GC inflammatory microenvironment, including macrophages,
lymphocytes, fibroblasts, and myeloid-derived suppressor cells [14,15], as well as their prod-
ucts (cytokines), which may promote tumor development at the initiation, progression, and
metastasis phases [14,16]. In this scenario, the presence of tumor-associated macrophages
(TAMs) is attracting attention because of its promising role in predicting prognosis and drug
resistance. Finally, in the era of immunotherapy, the research of TAM-targeted therapy could
represent an innovative approach to tailor-made treatments and to overcome resistance to
immune checkpoint inhibitors (ICIs) [16,17].

This review summarizes and discusses the current understanding of the inflammatory
TME in GC, focusing on the different types of tumor-associated cells and implications for
future therapeutic strategies.

2. Tumor-Associated Macrophages

Being a key component of tumor-infiltrating immune cells, macrophages play a crucial
role in tumorigenesis; as a matter of fact, they promote tumor growth and progression
and they are also involved in the development of treatment resistance [18]. Resident
macrophages and recruited circulating monocytes result in TAM accumulation in the
tumor mass, which generally correlates with poor prognosis across solid tumors [19].
Macrophages were initially supposed to enhance antitumor immunity, taking part in
innate host defense, recognizing non-self cells, and phagocyting them [20,21]. Neverthe-
less, increasing preclinical and clinical evidence has highlighted the controversial role of
macrophages in promoting cancer progression and metastatization [16]. Macrophages
display a continuum of activation states, which is influenced by the surrounding mi-
croenvironment [22,23]. Of note, recruited monocytes can turn into non-polarized (M0)
macrophages that differentiate into two distinct types of macrophages: “classically acti-
vated” or M1, which guide acute inflammatory responses, and “alternatively activated” or
M2, which are involved in tumor progression [24,25]. M1 macrophages contribute to am-
plify the type 1 immune response through the production of proinflammatory interleukins
(IL-12, IL-1, IL-6), tumor necrosis factor (TNF)-α, reactive oxygen species (ROS), and nitric
oxide (NO), which are found to cause epigenetic changes in the gastric epithelial cells
during HP infection [26,27]. Conversely, M2 macrophages are stimulated by the type 2 T
helper cell (Th2) cytokines (IL-4, IL-10, and IL-13) and exhibit pro-tumorigenic functions,
including tissue remodeling and tumor progression [28,29].

However, M2 macrophages are the most represented TAMs in the TME [30]. Preclinical
evidence showed that tumor and stroma cells release C–C motif chemokine ligand 2 (CCL2)
to recruit monocytes expressing C-C chemokine receptor type 2 (CCR2); these recruited
CCR2-expressing monocytes will finally polarize into TAMs, contributing to tumor cell
survival [31–33]. Thus, there is direct crosstalk between tumor cells and TAMs. Notably,
tumor cells can promote M2 polarization by expressing cytokines and growth factors
including colony-stimulating factor 1 (CSF-1) and IL-4 [23,34,35]. Conversely, TAMs can
secrete chemokines and cytokines, particularly IL-6, IL-8, and IL-10, that are involved in
tumor growth, angiogenesis, tumor invasion, and the depression of immunity [36]. Another fascinating function of TAMs in tumor progression is represented by their contribution to the formation of pre-metastatic niches (PMNs) [37]. PMNs constitute a peculiar tumor-growth-favoring microenvironment deprived of tumor cells, which is key to the survival and outgrowth of future metastatic disease [38]. Interestingly, TAMs are mobilized to the peripheral blood and then recruited in the PMNs by many tumor-secreted cytokines and growth factors (e.g., CCL2, CSF-1, VEGF, PLGF, TNF-α, TGF-β), tissue inhibitor of metalloproteinase (TIMP)-1, and exosomes [37,39,40].

Moreover, TAMs are able to profoundly modulate treatment response to chemotherapy, targeted drugs, antiangiogenic agents, immune checkpoint inhibitors (ICIs), as well as radiotherapy, resulting in treatment failure [25,41].

In GC, chronic inflammation of the gastric mucosa caused by HP infection has been established as an important risk factor in the development of the tumor, causing immune cell migration to the stomach and the production of chemokines and cytokines, which will eventually lead to the activation of survival signaling pathways and epithelial proliferation [13,42]. Unresolved inflammation derived from chronic infection with HP is one of the hallmarks of the TME in GC, which is enriched in myeloid-derived suppressor cells (MDSCs), regulatory T cells (Tregs), and TAMs [43]. In this scenario, TAMs contribute to attenuating the immune response via different pathways, including the production of anti-inflammatory cytokines (including IL-10 and TGF-β), prostaglandin E2 (PGE2), and the expression of programmed death-ligand 1 (PD-L1) [44]. In addition, TAMs play an important role in tumor neovascularization by secreting proangiogenic factors, such as VEGF, TNF, IL-1β, IL-8, PDGF, FGF, and others [45]. Finally, TAMs can also contribute to the invasiveness of tumor cells by remodeling the extracellular matrix, by expressing activated epithelial–mesenchymal transition (EMT) factor, and by promoting EMT, with invasion and migration properties [46,47].

Nevertheless, the prognostic role of TAMs in GC is still debated. In 2016, a meta-analysis including 12 studies investigated the correlation between TAM and patients’ survival, concluding that TAM infiltration and the number of infiltrating M2 macrophages might represent negative prognostic factors for GC patients [48]. In a second study by Lu et al., tumor-associated CD68+ macrophages were identified as an independent prognostic marker for recurrence-free survival (RFS), since patients with resectable GC with TAM infiltration were found to have poorer RFS [49]. Conversely, a recent study by Liu et al. demonstrated that M2 macrophage infiltration was found to be lower in signet ring cell carcinoma and mucinous adenocarcinoma, suggesting a potential positive prognostic factor [50]. Lastly, GC patients with peritoneal metastasis had increased levels of macrophages and alternatively activated macrophages in the peritoneum compared with those without peritoneal carcinomatosis [51].

A thorough understanding of the role of macrophages in tumor progression has led to the development of new, tailored therapeutic approaches. To date, macrophage-targeting strategies encompass a wide range of antibodies and small-molecule inhibitors [52]. Notably, the most important treatment strategy is represented by the inhibition of the colony-stimulating factor 1 (CSF1)–CSF1 receptor (CSF1R) axis, which is essential for macrophage survival and the transition from TAM M1 into TAM M2-type [53]. The CSF1R belongs to the platelet-derived growth factor family and, when it binds to its ligand CSF-1, it promotes myeloid differentiation, monocytic commitment, as well as the survival, proliferation, and recruitment of macrophages [16,53]. Furthermore, preclinical evidence showed that CSF1R blockade enhanced PD-1 and CTLA4 inhibitors’ activity, where ICIs showed limited efficacy [54].

Several monoclonal antibodies and tyrosine kinase inhibitors targeting CSF-1/CSF1R are being currently investigated as monotherapies or in combination in clinical trials and are summarized in Table 1.
Table 1. Clinical trials targeting tumor-associated macrophages in solid tumors, including gastric cancer.

| Drug | Target | Class of Drug | Mechanism of Action | Clinical Trials Identifier | Planned Enrollment | Design | Drug Combined with |
|------|--------|---------------|---------------------|----------------------------|--------------------|--------|---------------------|
| Emactuzumab (RG7155) | CSF1R | mAB | Directed against CSF1R expressed on macrophages, interfering with the CSF-1/CSF1R axis | NCT02323191 (completed)  NCT02760797 (completed)  NCT01494688 (completed)  NCT03335540 (recruiting)  NCT03431948 (active, not recruiting)  NCT02526017 (completed)  NCT03158272 (completed) | 221 pts  38 pts  217 pts  50 pts  60 pts  295 pts  19 pts | Phase I  Phase I  Phase I  Phase I  Phase I  Phase I  Phase I | Atezolizumab  Selicrelumab  Paclitaxel  Nivolumab  Nivolumab  Nivolumab |
| Cabiralizumab (FPA008) | CSF1R | mAB | Binds to to CSF1R and blocks its signaling, reducing TAMs and promoting a proinflammatory microenvironment and T-cell responses | NCT03335540 (recruiting)  NCT02526017 (completed)  NCT03158272 (completed) | 50 pts  295 pts  19 pts | Phase I  Phase I  Phase I | Nivolumab  Nivolumab  Nivolumab |
| IMC-CS4 | CSF1R | mAB | Directed against CSF1R, which may trigger ADCC in tumor cells overexpressing CSF1R. | NCT01346358 (completed)  NCT02880371 (completed)  NCT01316822 (completed) | 72 pts  82 pts  26 pts | Phase I  Phase I-II  Phase I | Nivolumab  +/- Pem-brolizumab  none |
| ARRY-382 | CSF1R | TKI | Orally administered, small-molecule macrophage CSF1R antagonist | NCT01346358 (completed) | 72 pts | Phase I | none |
| BLZ945 | CSF1R | TKI | Selectively binds to CSF1R expressed on TAMs, blocks the activity of CSF1R, and inhibits CSF1R-mediated signal transduction pathways. | NCT0289723 (recruiting) | 200 pts | Phase I | none |
| PLX7486 | CSF1R, TrkA, TrkB, TrkC | TKI | Selective inhibitor of CSF1R and TrkA, TrkB, and TrkC. | NCT01804530 (completed) | 59 pts | Phase I | none |

CSF1R: colony-stimulating factor 1 receptor; mAB: monoclonal antibody; pts participants; SBRT: Stereotactic Body Radiation Therapy; ADCC: antibody-dependent cell-mediated cytotoxicity; TKI: tyrosine kinase inhibitors; TAMs: tumor-associated macrophages; TrkA, TrkB, and TrkC: neurotrophic tyrosine kinase receptor types 1, 2, and 3.
3. Lymphocytes

Tumor-infiltrating lymphocytes (TILs) encompass a heterogeneous group of immune cells including B cells, T cells, and natural killer (NK) cells [55]. Among the biological mechanisms involved in anticancer immunity, T-cell adaptive immunity has been suggested to play a key role in this setting [56]; more specifically, CD8+ T cells, CD4+ T helper cells, FOXP3+ regulatory T cells, memory T cells, and NK cells can infiltrate the stromal tissue, thus modifying the host immune response against cancer cells [57,58]. Over the last decade, several reports have highlighted that the GC microenvironment could be associated with the infiltration of tumor lymphocytes [5,59]. TILs may cause potent anticancer responses, preventing tumor growth and eradicating cancer cells; moreover, TILs have been suggested to enhance inflammation through the secretion of chemokines, cytokines, and matrix metalloproteinases [60,61].

Because of the antitumor activity of T cells, patients with GC and high TILs have a better prognosis; conversely, PD-L1 expression seems to correlate with the more aggressive behavior of the disease [62,63]. In addition, a poorer prognosis was observed in GC patients showing high infiltration of FOXP3+ regulatory T cells [64,65]. In a landmark study conducted by Lee and colleagues encompassing 220 GC patients, the authors focused on the type and density of TILs and their respective roles in predicting the clinical outcome of GC [66]. The results showed that GC patients with CD3, CD4, and CD45RO TILs had prolonged survival, suggesting that TIL density could represent a predictor of regional lymph node involvement and survival in these patients. Furthermore, preclinical data have suggested that the presence of TILs may promote apoptosis in GC models, and thus, adaptive antitumor responses could be started in the GC microenvironment [27].

However, little information is available on the role of lymphocytes in GC preclinical models so far, and further efforts are needed to gain more insight into this promising, yet poorly studied, topic of GC management [67,68].

4. Cancer-Associated Fibroblasts

Among the numerous types of cells involved in the tumor microenvironment, cancer-associated fibroblasts (CAFs) play a key role in influencing tumor cell growth and migration (Figure 1) [69]. Conversely, these fibroblasts may also have an inhibitory action, as suggested by recent studies (Figure 2) [70,71]. Based on these premises, although targeting CAFs may represent a promising and emerging therapeutic strategy, their inhibition could also result in cancer-promoting effects.

In solid tumors rich in connective tissue, such as pancreatic cancer, CAFs have been described as large, spindle-like stromal cells [72]; interestingly, stromal tissue in physiological conditions presents a limited number of fibroblasts, and, over the last decade, genomic studies have reported the differences existing between CAFs and non-cancer fibroblasts in several solid tumors. In particular, the interaction between cancer and stromal tissue may result in the activation of CAFs [73]; when activated, these cells are able to produce soluble molecules, such as TGF-β, fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF), interleukins, and molecules of the vascular endothelial growth factor (VEGF) family [74]. All these elements play a crucial role in regulating tumor growth and phlogistic responses through different systems and present a higher proliferation rate compared with normal fibroblasts [75].

The role of normal fibroblasts in the tumor microenvironment is controversial and still largely debated, with the main topic of discussion involving their functions in influencing the metastasis process [76,77]; a study conducted by Xu and colleagues aimed at replicating the environment of cancer metastasis by coculturing normal fibroblasts in monolayers of GC cells [78]. The authors observed that some tumor cells developed spindle-like morphological features and showed an increased proliferation rate as well a higher invasive potential [78]; in addition, the loss of vimentin and the E-cadherin was observed in such cells, suggesting that normal fibroblasts are able to induce EMT in tumor cells, thus leading to cancer metastasis [78]. Based on these data, normal fibroblasts are deemed able to
switch their phenotype, showing CAF-like features when these cells grow in the GC microenvironment [14,79].

GCs have been frequently associated with abundant fibrosis, especially in the case of undifferentiated or poorly differentiated forms [34,80]. A study by Quante and colleagues observed an association between CAFs and GC progression and cell growth in murine models, due to the secretion of several factors—including, among others, CXCL12, IL-6, and Wnt5a [81]. These findings have been further confirmed by more recent reports, depicting specific roles for FGF, IL-6, and CXCL-12 in promoting tumor cell proliferation, and PDGF and IL-1 beta in stimulating epithelial–mesenchymal transition (EMT) (Figure 2) [82,83].

The origin of CAFs themselves is highly discussed in GC: it has been suggested that they derive from several cells, including pericytes, local physiological fibroblasts, and bone marrow mesenchymal cells (MSCs) [84,85]. According to recent reports, normal myofibroblasts may play an important role in originating CAFs [86,87]. Indeed, these cells seem to be involved in the secretion of R-spondin3, taking part in stem cell activity; moreover, during the process of mucosal inflammation and regeneration, myofibroblasts have been observed to promote proliferation and stem cell function [87,88]. Likewise, studies on GC murine models have highlighted that nearly one-fifth of the overall number of CAFs could originate from MSCs derived from bone marrow [89,90]. These findings have also been reported in patients with GCs and/or rectal adenomas following bone marrow transplantation [33,91]. Lastly, the gastrointestinal mucosa could represent another source of CAFs in GC, due to the presence of MSC-like cell types able to express Gremlin-1 [92].

Figure 1. Schematic representation of tumor-associated changes observed in the tumor microenvironment. As reported below, the tumor microenvironment (TME) encompasses both the acellular elements including blood vessels and the extracellular matrix and cellular components such as epithelial cells, immune cells, and fibroblasts. The release of specific molecules by tumor cells has been suggested to modify the TME, enhancing neoangiogenesis, immune evasion, metastasis niche formation, and other processes characterizing cancer growth and progression. Abbreviations: CAF: cancer-associated fibroblast; EMT: epithelial–mesenchymal transition; IL-1 beta: interleukin 1 beta; IL-6: interleukin 6; IL-10: interleukin 10; IL-35: interleukin 35; M1: M1-type macrophage; M2: M2-type macrophage; M-CSF: macrophage colony-stimulating factor; TGF-beta: tumor growth factor beta; T reg: regulatory T cells; VEGF: vascular endothelial growth factor.
Figure 2. Schematic figure representing the interplay between cancer-associated fibroblasts (CAFs) and gastric cancer (GC) cells. As reported in the text, several cells represent sources of CAFs, including bone-marrow-derived cells (BMDCs), local pericytes, and normal fibroblasts, with the latter supporting GC stem cells through the secretion of R-spondin3. CAFs are able to regulate tumor growth and progression through the secretion of several molecules—such as IL-6, CXCL-12, PDGF, EGF, and FGF. Vascular endothelial growth factor A (VEGFA), CXCL12, fibroblast growth factor 2 (FGF2), and platelet-derived growth factor (PDGF) produced by CAFs facilitate the formation of new blood vessels in the TME. CAFs secrete also many chemokines and cytokines, such as CXC chemokine ligand 12 (CXCL12) and transforming growth factor-β (TGF-β), inducing immunosuppression in the TME. Notably enough, a subpopulation of CAFs has been suggested to exert also an inhibitory action on tumor cells. Abbreviations: BMDCs: bone-marrow-derived cells; CAF: cancer-associated fibroblast.

The interaction between CAFs and tumor cells represents a fundamental process that is currently being investigated, with the aim of developing specific inhibitors in this setting. As previously mentioned, CAFs secrete IL-6, which has an important role in inflammatory as well as immune responses; in particular, the secretion of IL-6 is enhanced in HP-related GC [93,94]. In fact, the induction of the cyclooxygenase-2 (COX-2)/prostaglandin E2 cascade induced by HP infection leads to the hypermethylation of miR-149 in CAFs, eventually resulting in increased IL-6 secretion [94]. Based on these premises and given the role played by IL-6 in inducing EMT through the JAK2/STAT3 pathway, recent studies have investigated the role of neutralizing antibodies, including AG490 [95,96]. A study conducted by Wu and colleagues has suggested that the simultaneous inhibition of JAK2/STAT3 and IL-6 using AG490 might impair tumor diffusion induced by CAFs to the peritoneum; as such, IL-6-targeted therapies could represent a complementary treatment approach due to their action on fibroblasts [97].

CAFs are also involved in the expression of several other molecules, including VEGF, FGF, CXCL-12, and HGF [98,99]. HGF is able to induce the activation of MET tyrosine kinase, and HGF/MET has been suggested to be involved in oncogenesis and disease
progression in GC [100]. Similar to IL-6, HGF inhibitors are currently being tested, with some of these agents already demonstrating encouraging results in inhibiting the transition of physiological fibroblasts into CAFs, both in vitro and in vivo [101]. In addition, the role of CAFs as a mechanism of resistance to fluoropyrimidines in GC patients is also being studied, with preliminary reports suggesting that complementary treatments inhibiting CAFs may overcome resistance to 5-fluorouracil [102,103].

Lastly, other promising therapeutic options include triptolide and tranilast [104]. Triptolide is a diterpenoid triepoxide derived from the herb Tripterygium wilfordii, which has been used as a natural agent; preclinical studies have suggested that triptolide treatment may inhibit the migration-, formation-, and invasion-promoting action of CAFs in GC [104]; in addition, this agent has been shown to downregulate microRNA-301a expression, while upregulating microRNA-149 expression in CAFs, a process leading to increased production of tumor-suppressive factors and to the inhibition of the secretion of the oncogenic IL-6. Finally, triptolide may impair the induction of EMT in GC cells by CAFs. Tranilast (N-[3,4-dimethoxycinnamoyl]-anthranilic acid) inhibits the release of chemical mediators from mast cells and it is used as an anti-allergic agent clinically; in oncology, it has shown an inhibitory action towards the interaction between GC cells and CAFs, through the inhibition of GC growth and fibrosis; thus, tranilast has been suggested to prevent peritoneal dissemination in GC preclinical models [105].

Currently, a large number of potentially meaningful clinical targets is under assessment in GC patients with CAFs inhibition, surely being a novel and promising anticancer strategy; however, investigational CAF-targeted therapies need further validation, and effective drugs against CAFs are currently lacking [105,106]. The results of ongoing trials are eagerly awaited in this setting.

5. Mesenchymal Stem Cells

As schematically reported in Figure 1, mesenchymal stem cells (MSCs) within the tumor microenvironment are able to differentiate into CAFs and tumor-associated MSCs, following their migration to tumors [107,108]. From a molecular point of view, MSCs play a stimulating action towards the angiogenetic process, due to the secretion of FGF, PDGF, and VEGF [109,110]; in fact, MSCs enhance the metastatic potential of tumor cells and favor drug resistance. Based on their potential role, MSCs are being investigated as therapeutic targets in solid tumors; specifically, MSCs might act as drug vehicles, given their marked tendency to be home to cancer sites (Table 2) [111,112]. For example, a phase I/II study evaluated the role of MSCs in gastrointestinal malignancies, including GC (NCT02008539); the trial assessed the role of modified MSCs combined with ganciclovir, reporting promising results in terms of both safety and efficacy [113].

Another therapeutic strategy including modified MSCs is based on the expression of cytosine deaminase and the co-administration of 5-fluorocytosine; such a combination was shown to inhibit gastrointestinal cancer cells’ growth in immunocompromised murine models [114–116]. In addition, apoptosis-inducing factors are also being evaluated within phase I and II studies exploring the role of oncolytic measles virus encoding thyroidal sodium iodide symporter (MV-NIS)-infected MSCs (NCT02068794); however, further efforts are needed to clarify whether MSCs could enter into clinical practice, confirming their potential in GC therapy.
| NCT Name        | Phase | Setting                                      | Treatment                                                                 | Recruitment Status | Estimated Enrolment | Primary Outcomes |
|-----------------|-------|----------------------------------------------|---------------------------------------------------------------------------|--------------------|---------------------|------------------|
| NCT02008539     | I/II  | Advanced gastrointestinal malignancies       | MSC_apceth_101                                                          | Terminated         | 13                  | Safety           |
| NCT02068794     | I/II  | Relapsed fallopian tube, peritoneal, or ovarian cancer | Oncolytic measles virus encoding thyroidal sodium iodide symporter (MV-NIS)-infected mesenchymal stem cells | Recruiting         | 57                  | MTD              |
| NCT03298763     | I/II  | Advanced non-small-cell lung cancer          | Targeted stem cells expressing TRAIL                                      | Recruiting         | 46                  | RP2D Tumor response rate |

RP2D: recommended Phase II dose; MTD: maximum tolerated dose.

6. Immunotherapy and TME in Gastric Cancer

Pathways regulating the immune system are called immune checkpoints: different cancer types use these immune checkpoints as a mechanism of immune evasion, leading to tumor progression [117,118]. The dependence of cancer on these pathways has been therapeutically exploited with the development of specific immune checkpoint inhibitors (ICI) such as anti-programmed cell death 1 (anti-PD-1) and anti-PD-1 ligand (anti-PD-L1) antibodies. By blocking the PD-1 axis with anti-PD-1 or anti-PD-L1 monoclonal antibodies, anti-tumor immune responses can be restored, leading to tumor regression. Briefly, PD-1 is a negative co-stimulatory transmembrane protein expressed on T-cells, B-cells, and NK cells; its binding to PD-L1 (which is expressed on tumor cells) and PD-L2 leads to peripheral T effector cell modulation as well as to tumor cell apoptosis and increased conversion of T effector cells to Treg cells [118].

In GC, pembrolizumab and nivolumab (both anti-PD-1 antibodies) have demonstrated survival benefit and gained regulatory approval in advanced settings; namely, pembrolizumab received accelerated approval for treatment of PD-L1-positive GC in third-line or later treatment by the US Food and Drug Administration (FDA) and for the treatment of patients with unresectable or metastatic, microsatellite instability-high (MSI-H), or mismatch repair-deficient (MMR-D) solid tumors that have progressed following prior treatment [118].

TME and stromal extracellular matrix (ECM) proteins can have an immune-modulatory functions, thus contributing to the immune evasion of cancer cells [119,120]. Immune surveillance is able to monitor, detect, and destroy cancer cells; however, as tumor progresses, cancer cells develop various mechanisms of immune evasion, leading to the development and the invasiveness of the tumor. A highly immunosuppressive microenvironment has been recently associated with the cross-talk between non-tumor-cell mesenchymal stromal cells (MSCs) and TAMs [121]. Namely, the differentiation from myeloid cells into M2-polarized macrophages, which, as mentioned before, are extremely immunosuppressive, seems to be mainly driven by exosomes produced by MSCs. Moreover, the interactions between pro-inflammatory macrophages and MSCs, mainly mediated by CD54, can lead to an increase in the immunosuppressive activity of MSCs [121]. As such, the blockade of such a network between MSCs and TAMs may represent a new therapeutic target to exploit in order to restore immune tolerance and improve clinical outcomes in GC patients.

Finally, although immunotherapy can result in long-lasting and major responses, a large portion of patients, however, do not benefit from this therapeutic approach, either from the beginning (i.e., primary resistance) or progressing after an initial response (i.e., acquired resistance). TAMs can limit the efficacy of immunotherapies, playing a tumor-
supportive role; moreover, they can also reprogram MSCs to a state which is ideal for immunotherapy resistance in the tumor niche [120]. Interactions between MSCs and TAMs are complex and may represent a promising target for immunotherapy; however, the molecular and cellular mechanisms underlying these interactions have not been thoroughly identified and further evidence is still warranted.

7. Conclusions

The TME represents a “complex society” composed of a wide spectrum of cell types and their extracellular matrix, where inflammation acts as primum movens in creating the TME and gastric carcinogenesis. This review provides an overview of available evidence of the inflammatory TME in gastric cancer, highlighting different types of tumor-associated cells and implications for future therapeutic strategies. As of today, several agents and therapeutic strategies targeting the TME are currently under assessment in both preclinical and clinical studies. Understanding the precise biology of the tumor microenvironment is a matter of topical and urgent importance and several preclinical and clinical strategies are currently under evaluation to target subpopulations of specific cells in this setting. Besides the progress in molecular and cellular biology, an improved understanding of the tumor microenvironment as a whole, with its complex network of cells and cytokines, will contribute to the development of promising new therapeutic approaches in the treatment of GC.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: No new data were created or analyzed in this study. Data sharing is not applicable to this review.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021, 1, 1–41.
2. Smyth, E.C.; Nilsson, M.; Grabsch, H.I.; van Grieken, N.C.; Lordick, F. Gastric cancer. Lancet 2020, 396, 635–648. [CrossRef]
3. Smyth, E.C.; Cervantes, A. Addition of nivolumab to chemotherapy in patients with advanced gastric cancer: A relevant step ahead, but still many questions to answer. ESMO Open 2020, 5, 1107. [CrossRef] [PubMed]
4. Moehler, M.; Shitara, K.; Garrido, M.; Salman, P.; Shen, L.; Wyrwicz, L.; Yamaguchi, K.; Skoczylas, T.; Campos Bragagnoli, A.; Liu, T.; et al. LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJCG/eophageal adenocarcinoma (EAC): First results of the CheckMate 649 study. Ann. Oncol. 2020, 31. [CrossRef]
5. Renzulli, M.; Clemente, A.; Spinelli, D.; Ierardi, A.M.; Marasco, G.; Farina, D.; Brochi, S.; Ravaioli, M.; Pettinari, I.; Cescon, M.; et al. Gastric cancer staging: Is it time for magnetic resonance imaging? Cancers 2020, 12, 1402. [CrossRef] [PubMed]
6. Rizzo, A.; Mollica, V.; Ricci, A.D.; Maggio, I.; Massucci, M.; Rojas Limpe, F.L.; Fabio, F.D.; Ardizzoni, A. Third- and later-line treatment in advanced or metastatic gastric cancer: A systematic review and meta-analysis. Future Oncol. 2020, 16, 4409–4418. [CrossRef] [PubMed]
7. Lauren, P. The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol. Microbiol. Scand. 1965, 64, 31–49. [CrossRef]
8. World Health Organization (WHO). Classification of tumours. In Digestive System Tumours; International Agency for Research on Cancer: Lyon, France, 2019; ISBN 9789283244998.
9. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014, 513, 202–209. [CrossRef]
10. Sohn, B.H.; Hwang, J.-E.; Jang, H.-J.; Lee, H.-S.; Oh, S.C.; Shim, J.-J.; Lee, K.-W.; Kim, E.H.; Yim, S.Y.; Lee, S.H.; et al. Clinical significance of four molecular subtypes of gastric cancer identified by the Cancer Genome Atlas Project. Clin. Cancer Res. 2017. [CrossRef]
11. Ricci, A.D.; Rizzo, A.; Brandi, G. DNA damage response alterations in gastric cancer: Knocking down a new wall. Future Oncol. 2021. [CrossRef]
12. Moehler, M.; Göpffert, K.; Lenz, H.-J. Outlook: Immunotherapy in gastrointestinal carcinoma—Innovative strategies. Oncol Res Treat. 2018, 41, 313–315. [CrossRef]
13. Sokolova, O.; Naumann, M. Crossstalk between DNA damage and inflammation in the multiple steps of gastric carcinogenesis. Curr. Top. Microbiol. Immunol. 2019, 421, 107–137.
14. Baj, J.; Brzozowska, K.; Forma, A.; Maani, A.; Sitarz, E.; Portincasa, P. Immunological aspects of the tumor microenvironment and epithelial-mesenchymal transition in gastric carcinogenesis. Int. J. Mol. Sci. 2020, 21, 2544. [CrossRef] [PubMed]
15. Uppal, A.; Dehal, A.; Chang, S.-C.; Barak, D.; Naeini, Y.; Jalas, J.R.; Bilchik, A.J. The immune microenvironment impacts survival in western patients with gastric adenocarcinoma. J. Gastrointest. Surg. 2020, 24, 28–38. [CrossRef]
16. Gambardella, V.; Castillo, J.; Tarazona, N.; Gimeno-Ciarpaglini, C.; Cabeza-Segura, M.; Roselló, S.; Roda, D.; Huerta, M.; Cervantes, A.; et al. The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target. Cancer Treat. Rev. 2020, 86, 102015. [CrossRef] [PubMed]
17. Ge, Z.; Ding, S. The crosstalk between tumor-associated macrophages (TAMs) and tumor cells and the corresponding targeted therapy. Front. Oncol. 2020, 10, 590941. [CrossRef] [PubMed]
18. Van Overmeire, E.; Laoui, D.; Keirse, J.; Van Ginderachter, J.A.; Sarukhan, A. Mechanisms driving macrophage diversity and specialization in distinct tumor microenvironments and parallelisms with other tissues. Front. Immunol. 2014, 5, 127. [CrossRef]
19. Vinogradov, S.; Warren, G.; Wei, X. Macrophages associated with tumors as potential targets and therapeutic intermediates. Nanomedicine 2014, 9, 695–707. [CrossRef]
20. Chen, Y.; Song, Y.; Du, W.; Gong, L.; Chang, H.; Zou, Z. Tumor-associated macrophages: An accomplice in solid tumor progression. J. Biomed. Sci. 2019, 26, 78. [CrossRef]
21. Condeelis, J.; Pollard, J.W. Macrophages: Obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006, 124, 263–266. [CrossRef]
22. Mosser, D.M.; Edwards, J.P. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 2008, 8, 958–969. [CrossRef]
23. Coussens, L.M.; Zitvogel, L.; Palucka, A.K. Neutralizing tumor-promoting chronic inflammation: A magic bullet? Science 2013, 339, 286–291. [CrossRef]
24. Kim, J.; Bae, J.-S. Tumor-associated macrophages and neutrophils in tumor microenvironment. Mediat. Inflamm. 2016, 2016, 6058147. [CrossRef] [PubMed]
25. Qiu, S.-Q.; Waijier, S.J.H.; Zwager, M.C.; de Vries, E.G.E.; van der Vegt, B.; Schröder, C.P. Tumor-associated macrophages in breast cancer: Innocent bystander or important player? Cancer Treat. Rev. 2018, 70, 178–189. [CrossRef] [PubMed]
26. Atri, C.; Guerfali, F.Z.; Laouini, D. Role of human macrophage polarization in inflammation during infectious diseases. Int. J. Mol. Sci. 2018, 19, 1801. [CrossRef] [PubMed]
27. Lee, K.; Hwang, H.; Nam, K.T. Immune response and the tumor microenvironment: How they communicate to regulate gastric cancer. Gut Liver 2014, 8, 131–139. [CrossRef]
28. Petersen, C.P.; Meyer, A.R.; De Salvo, C.; Choi, E.; Schlegel, C.; Petersen, A.; Engevik, A.C.; Prasad, N.; Levy, S.E.; Peebles, R.S.; et al. A signalling cascade of IL-33 to IL-13 regulates metaplasia in the mouse stomach. Gut 2018, 67, 805–817. [CrossRef]
29. Biswas, S.K.; Mantovani, A. Macrophage plasticity and interaction with lymphocyte subsets: Cancer as a paradigm. Nat. Immunol. 2010, 11, 889–896. [CrossRef]
30. Mantovani, A.; Sozzani, S.; Locati, M.; Allavena, P.; Sica, A. Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002, 23, 549–555. [CrossRef]
31. Qian, B.-Z.; Li, J.; Zhang, H.; Kitamura, T.; Zhang, J.; Campion, L.R.; Kaiser, E.A.; Snyder, L.A.; Pollard, J.W. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011, 475, 222–225. [CrossRef]
32. Li, X.; Yao, W.; Yuan, Y.; Chen, P.; Li, B.; Li, J.; Chu, R.; Song, H.; Xie, D.; Jiang, X.; et al. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma. Gut 2017, 66, 157–167. [CrossRef]
33. Pan, Y.; Yu, Y.; Wang, X.; Zhang, T. Tumor-associated macrophages in tumor immunity. Front. Immunol. 2020, 11, 583084. [CrossRef] [PubMed]
34. Oya, Y.; Hayakawa, Y.; Koike, K. Tumor microenvironment in gastric cancers. Cancer Sci. 2020, 111, 2696–2707. [CrossRef] [PubMed]
35. Veremeyko, T.; Yung, A.W.Y.; Anthony, D.C.; Strekalova, T.; Ponomarev, E.D. Early growth response gene-2 is essential for M1 and M2 macrophage activation and plasticity by modulation of the transcription factor CEBPβ. Front. Immunol. 2018, 9, 2515. [CrossRef]
36. Zhou, J.; Tang, Z.; Gao, S.; Li, C.; Feng, Y.; Zhou, X. Tumor-associated macrophages: Recent insights and therapies. Front. Oncol. 2020, 10, 188. [CrossRef] [PubMed]
37. Lin, Y.; Xu, J.; Lan, H. Tumor-associated macrophages in tumor metastasis: Biological roles and clinical therapeutic applications. J. Hematol. Oncol. 2019, 12, 76. [CrossRef] [PubMed]
38. Peinado, H.; Zhang, H.; Matei, I.R.; Costa-Silva, B.; Hoshino, A.; Rodrigues, G.; Psaila, B.; Kaplan, R.N.; Bromberg, J.F.; Kang, Y.; et al. Pre-metastatic niches: Organ-specific homes for metastases. Nat. Rev. Cancer 2017, 17, 302–317. [CrossRef] [PubMed]
39. Quail, D.F.; Joyce, J.A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 2013, 19, 1423–1437. [CrossRef]
65. Won, K.Y.; Kim, G.Y.; Kim, H.K.; Choi, S.I.; Kim, S.H.; Bae, G.E.; Lim, J.U.; Lim, S.-J. Tumoral FOXP3 expression is associated with favorable clinicopathological variables and good prognosis in gastric adenocarcinoma: The tumor suppressor function of tumoral FOXP3 is related with the P21 expression in gastric adenocarcinoma. *Hum. Pathol.* **2017**, *68*, 112–118. [CrossRef] [PubMed]

66. Lee, H.E.; Chae, S.W.; Lee, Y.J.; Kim, M.A.; Lee, H.S.; Lee, B.L.; Kim, W.H. Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. *Br. J. Cancer* **2008**, *99*, 1704–1711. [CrossRef]

67. Refolo, M.G.; Lotesoriere, C.; Messa, C.; Caruso, M.G.; D’Alessandro, R. Integrated immune gene expression signature and molecular classification in gastric cancer: New insights. *J. Leukoc. Biol.* **2020**, *108*, 633–646. [CrossRef] [PubMed]

68. Kang, B.W.; Kim, J.G.; Lee, I.H.; Bae, H.I.; Seo, A.N. Clinical significance of tumor-infiltrating lymphocytes for gastric cancer in the era of immunology. *World J. Gastrointest. Oncol.* **2017**, *9*, 293–299. [CrossRef]

69. Chen, X.; Song, E. Turning foes to friends: Targeting cancer-associated fibroblasts. *Nat. Rev. Drug Discov.* **2019**, *18*, 99–115. [CrossRef] [PubMed]

70. Kalluri, R. The biology and function of fibroblasts in cancer. *Nat. Rev. Cancer* **2016**, *16*, 582–598. [CrossRef]

71. Kobayashi, H.; Enomoto, A.; Woods, S.L.; Burt, A.D.; Takahashi, M.; Worthley, D.L. Cancer-associated fibroblasts in gastrointestinal cancer. *Nat. Rev. Gastroenterol. Hepatol.* **2019**, *16*, 282–295. [CrossRef]

72. Hosein, A.N.; Brekken, R.A.; Maitra, A. Pancreatic cancer stroma: An update on therapeutic targeting strategies. *Ann. Gastroenterol. Surg.* **2020**, *4*, 464–474. [CrossRef] [PubMed]

73. Dvořáková, B.; Lacina, L.; Smetana, K., Jr. Isolation of normal fibroblasts and their cancer-associated counterparts (CAFs) for biomedical research. *Methods Mol. Biol.* **2019**, *1879*, 393–406. [PubMed]

74. Mitra, A.K.; Zillhardt, M.; Hua, Y.; Tiwari, P.; Murmann, A.E.; Peter, M.E.; Lengyel, E. MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer. *Cancer Discov.* **2012**, *2*, 1100–1108. [CrossRef]

75. Cho, H.; Seo, Y.; Loke, K.M.; Kim, S.-W.; Oh, S.-M.; Kim, J.-H.; Soh, J.; Kim, H.S.; Lee, H.; Kim, J.; et al. Cancer-stimulated CAFs enhance monocyte differentiation and protumoral TAM activation via IL6 and GM-CSF secretion. *Clin. Cancer Res.* **2018**, *24*, 5407–5421. [CrossRef] [PubMed]

76. Reina-Campos, M.; Moscat, J.; Diaz-Meco, M. Metabolism shapes the tumor microenvironment. *Curr. Opin. Cell Biol.* **2017**, *48*, 47–53. [CrossRef] [PubMed]

77. Kuzet, S.-E.; Gaggioli, C. Fibroblast activation in cancer: When seed fertilizes soil. *Cell Cycle* **2010**, *9*, 2019–2020. [PubMed]

78. Xu, W.; Hu, X.; Chen, Z.; Zheng, X.; Zhang, C.; Wang, G.; Chen, Y.; Zhou, X.; Tang, X.; Luo, L.; et al. Normal fibroblasts induce E-cadherin loss and increase lymph node metastasis in gastric cancer. *PLoS ONE* **2014**, *9*, e97306. [CrossRef]

79. Kozak, J.; Forma, A.; Czecelewski, M.; Kozyra, P.; Sitarz, E.; Radzikowska-Büchner, E.; Sitarz, M.; Baj, J. Inhibition or reversal of the epithelial-mesenchymal transition in gastric cancer: Pharmacological approaches. *Int. J. Mol. Sci.* **2020**, *22*, 277. [CrossRef] [PubMed]

80. Ham, I.-H.; Lee, D.; Hur, H. Role of cancer-associated fibroblast in gastric cancer progression and resistance to treatments. *J. Oncol.* **2019**, *2019*, 6270784. [CrossRef]

81. Quante, M.; Tu, S.P.; Tomita, H.; Gonda, T.; Wang, S.S.W.; Takashi, S.; Baik, G.H.; Shibata, W.; Diprete, B.; Betz, K.S.; et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. *Cancer Cell* **2011**, *19*, 257–272. [CrossRef]

82. Fiori, M.E.; Di Franco, S.; Villanova, L.; Bionca, P.; Stassi, G.; De Maria, R. Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance. *Cancers* **2015**, *7*, 2054–2062. [CrossRef] [PubMed]

83. De Francesco, E.M.; Maggiolini, M.; Musti, A.M. Crosstalk between Notch, HIF-1α and GPER in Breast Cancer EMT. *Int. J. Mol. Sci.* **2018**, *19*, 20111. [CrossRef] [PubMed]

84. Minami, T.; Aoyagi, K.; Kawahara, A.; Murakami, N.; Isobe, T.; Tanaka, Y.; Kaku, H.; Fujita, F.; Akagi, Y. Evaluation of the expression of bone marrow-derived mesenchymal stem cells and cancer-associated fibroblasts in the stroma of gastric cancer tissue. *Ann. Gastroenterol. Surg.* **2020**, *4*, 464–474. [CrossRef] [PubMed]

85. Zhang, Q.; Wang, M.; Huang, F.; Yang, T.; Cai, J.; Zhang, X.; Zhu, W.; Qian, H.; Xu, W.H. pylori infection-induced MSC differentiation into CAFs promotes epithelial-mesenchymal transition in gastric epithelial cells. *Int. J. Mol. Med.* **2013**, *32*, 1465–1473. [CrossRef] [PubMed]

86. Yamaguchi, H.; Sakai, R. Direct Interaction between carcinoma cells and cancer associated fibroblasts for the regulation of cancer invasion. *Cancers* **2015**, *7*, 2054–2062. [CrossRef] [PubMed]

87. Sigal, M.; Logan, C.Y.; Kapalczynska, M.; Mollenkopf, H.-J.; Berger, H.; Wiedenmann, B.; Nuße, R.; Amiev, M.R.; Meyer, T.F. Stromal R-spondin orchestrates gastric epithelial stem cells and gland homeostasis. *Nature* **2017**, *548*, 451–455. [CrossRef]

88. Xiao, S.; Zhou, L. Gastric Stem Cells: Physiological and Pathological Perspectives. *Front. Cell Dev. Biol.* **2020**, *8*, 571536. [CrossRef] [PubMed]

89. Bubnovskaya, L.; Osinsky, D. Tumor microenvironment and metabolic factors: Contribution to gastric cancer. *Exp. Oncol.* **2020**, *42*, 2–10. [CrossRef]

90. Rojas, A.; Araya, P.; Gonzalez, I.; Morales, E. Gastric tumor microenvironment. *Adv. Exp. Med. Biol.* **2020**, *1226*, 23–35.

91. Weiss, A.L.; Simmons, J.G.; Jobin, C.; Lund, P.K. Tumor necrosis factor (TNF) alpha increases collagen accumulation and proliferation in intestinal myofibroblasts via TNF receptor 2. *J. Biol. Chem.* **2005**, *280*, 36099–36109. [CrossRef]

92. Worthley, D.L.; Churchill, M.; Compton, J.T.; Tailor, Y.; Rao, M.; Si, Y.; Levin, D.; Schwartz, M.G.; Uygur, A.; Hayakawa, Y.; et al. Gremlin 1 identifies a skeletal stem cell with bone, cartilage, and reticular stromal potential. *Cell* **2015**, *160*, 269–284. [CrossRef]
93. Li, P.; Shan, J.-X.; Chen, X.-H.; Zhang, D.; Su, L.-P.; Huang, X.-Y.; Yu, B.-Q.; Zhi, Q.-M.; Li, C.-L.; Wang, Y.-Q.; et al. Epigenetic silencing of microRNA-149 in cancer-associated fibroblasts mediates prostaglandin E2/interleukin-6 signaling in the tumor microenvironment. Cell Res. 2015, 25, 388–603. [CrossRef]

94. Taniguchi, K.; Karin, M. IL-6 and related cytokines as the critical lymphpins between inflammation and cancer. Semin. Immunol. 2014, 26, 54–74. [CrossRef]

95. Qureshy, Z.; Johnson, D.E.; Grandis, J.R. Targeting the JAK/STAT pathway in solid tumors. J. Cancer Metastasis Treat. 2020, 6, 389. [CrossRef]

96. Linares, J.; Marín-Jiménez, J.A.; Badia-Ramentol, J.; Calon, A. Determinants and functions of CAFs secretome during cancer progression and therapy. Front. Cell Dev. Biol. 2020, 8, 621070. [CrossRef] [PubMed]

97. Wu, X.; Tao, P.; Zhou, Q.; Li, J.; Yu, Z.; Wang, X.; Li, J.; Li, C.; Yan, M.; Zhi, Q.; et al. IL-6 secreted by cancer-associated fibroblasts promotes epithelial-mesenchymal transition and metastasis of gastric cancer via JAK2/STAT3 signaling pathway. Oncotarget 2017, 8, 20741–20750. [CrossRef] [PubMed]

98. Huang, T.-X.; Guan, X.-Y.; Fu, L. Therapeutic targeting of the crosstalk between cancer-associated fibroblasts and cancer stem cells. Am. J. Cancer Res. 2019, 9, 1889–1904.

99. Konforonu, A.; Lowengrub, J.S. Activation of the HGF/c-Met axis in the tumor microenvironment: A multispecies model. J. Theor. Biol. 2018, 439, 86–99. [CrossRef] [PubMed]

100. Anestis, A.; Zoi, I.; Karamouzis, M.V. Current advances of targeting HGF/c-Met pathway in gastric cancer. Ann. Transl. Med. 2018, 6, 247. [CrossRef]

101. Wu, X.; Chen, X.; Zhou, Q.; Li, P.; Yu, B.; Li, J.; Qu, Y.; Yan, J.; Yu, Y.; Yan, M.; et al. Hepatocyte growth factor promotes tumor stromal fibroblasts to promote tumorigenesis in gastric cancer. Cancer Lett. 2013, 335, 128–135. [CrossRef]

102. Ma, Y.; Zhu, J.; Chen, S.; Li, T.; Ma, J.; Guo, S.; Hu, J.; Yue, T.; Zhang, J.; Wang, P.; et al. Activated gastric cancer-associated fibroblasts contribute to the malignant phenotype and 5-FU resistance via paracrine action in gastric cancer. Cancer Cell Int. 2018, 18, 104. [CrossRef] [PubMed]

103. Zhang, H.; Deng, T.; Liu, R.; Ning, T.; Yang, H.; Liu, D.; Zhang, Q.; Lin, D.; Ge, S.; Bai, M.; et al. CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemotherapy-resistance in gastric cancer. Mol. Cancer 2020, 19, 43. [CrossRef] [PubMed]

104. Xiang, S.; Zhao, Z.; Zhang, T.; Zhang, B.; Meng, M.; Cao, Z.; Zhou, Q. Triptoreline suppresses gastric tumor growth and metastasis through inhibition of the oncogetic Notch1 and NF-κB signaling pathways. Toxicol. Appl. Pharmacol. 2020, 388, 114870. [CrossRef] [PubMed]

105. Saito, H.; Fushida, S.; Harada, S.; Miyashita, S.; Oyama, K.; Yamaguchi, T.; Tsukada, T.; Kinoshita, J.; Tajima, H.; Ninomiya, I.; et al. Importance of human peritoneal mesothelial cells in the progression, fibrosis, and control of gastric cancer: Inhibition of growth and ferroptosis by tranilast. Gastric Cancer 2018, 21, 55–67. [CrossRef] [PubMed]

106. Lordick, F.; Shiota, K.; Janjigian, Y.Y. New agents on the horizon in gastric cancer. Ann. Oncol. 2017, 28, 1767–1775. [CrossRef]

107. Huang, F.; Wang, M.; Yang, T.; Cai, J.; Zhang, Q.; Sun, Z.; Wu, X.; Zhang, X.; Zhu, W.; Qian, H.; et al. Gastric cancer-derived MSC-secreted PDGF-DD promotes gastric cancer progression. J. Cancer Res. Clin. Oncol. 2014, 140, 1835–1848. [CrossRef]

108. Li, W.; Zhang, X.; Wu, F.; Zhou, Y.; Bao, Z.; Li, H.; Zheng, P.; Zhao, S. Gastric cancer-derived mesenchymal stromal cells trigger M2 macrophage polarization that promotes metastasis and EMT in gastric cancer. Cell Death Dis. 2019, 10, 918. [CrossRef]

109. Zhou, Y.-L.; Li, Y.-M.; He, W.-T. Apoptosis of mesenchymal stem cells in the targeted gene therapy for gastric cancer. Curr. Stem Cell Res. Ther. 2016, 11, 434–439. [CrossRef]

110. Cecchi, F.; Rabe, D.C.; Bottaro, D.P. Targeting the HGF/Met signaling pathway in cancer therapy. Expert Opin. Ther. Targets 2012, 16, 553–572. [CrossRef]

111. Atiya, H.; Frisbie, L.; Pressimone, C.; Coffman, L. Mesenchymal stem cells in the tumor microenvironment. Adv. Exp. Med. Biol. 2020, 1234, 31–42. [PubMed]

112. Liang, W.; Chen, X.; Zhang, S.; Fang, J.; Chen, M.; Xu, Y.; Chen, X. Mesenchymal stem cells as a double-edged sword in tumor growth: Focusing on MSC-derived cytokines. Cell. Mol. Biol. Lett. 2021, 26, 3. [CrossRef] [PubMed]

113. von Einem, J.C.; Guenther, C.; Volk, H.-D.; Grütz, G.; Hirsch, D.; Salat, C.; Stoezter, O.; Nelson, P.J.; Michl, M.; Modest, D.P.; et al. Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells: Results from the phase 1/2 TREAT-ME-1 trial. Int. J. Cancer 2019, 145, 1538–1546. [CrossRef] [PubMed]

114. He, W.; Liang, B.; Wang, C.; Li, S.; Zhao, Y.; Huang, Q.; Liu, Z.; Yao, Z.; Wu, Q.; Liao, W.; et al. MSC-regulated lncRNA MACC1-AS1 promotes stemness and chemoresistance through fatty acid oxidation in gastric cancer. Oncogene 2019, 38, 4637–4654. [CrossRef] [PubMed]

115. Kucerova, L.; Altanerova, V.; Matuskova, M.; Tyciakova, S.; Altaner, C. Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy. Cancer Res. 2007, 67, 6304–6313. [CrossRef]

116. Albini, A.; Magnani, E.; Noonan, D.M. The tumor microenvironment: Biology of a complex cellular and tissue society. Q. J. Nucl. Med. Mol. Imaging 2010, 54, 244–248. [PubMed]

117. Pardoll, D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer. 2012, 12, 252–264. [CrossRef]

118. Sundar, R.; Smyth, E.C.; Peng, S.; Yeong, J.P.S.; Tan, P. Predictive biomarkers of immune checkpoint inhibition in gastroesophageal cancers. Front. Oncol. 2020, 10, 763. [CrossRef]

119. Ma, H.-Y.; Liu, X.-Z.; Liang, C.-M. Inflammatory microenvironment contributes to epithelial-mesenchymal transition in gastric cancer. World J. Gastroenterol. 2016, 22, 6619–6628. [CrossRef]
120. Gamradt, P.; De La Fourchadière, C.; Hennino, A. Stromal protein-mediated immune regulation in digestive cancers. *Cancers* 2021, *13*, 146. [CrossRef]

121. Zheng, P.; Li, W. Crosstalk between mesenchymal stromal cells and tumor-associated macrophages in gastric cancer. *Front. Oncol.* 2020, *10*, 571516. [CrossRef] [PubMed]